0
 

CSL Behring-Company profile, Business Overview, Financial Performance, Operating Segments, Strategic Moves, and Competitive Intelligence Report

  • ID: CPS__175749
  • June 2017
  • 8 pages
  • Price: $ 95
 
 

IVIG is a sterile solution of antibodies collected from healthy donors, which is administered through the veins into the body. Currently, the immunoglobulin industry is growing on account of increasing FDA/EMA approvals and government support. IVIG usage against the conditions within the criteria (i.e. FDA/EMA approved indications) have increased greatly and the largest increase found in Chronic Inflammatory demyelinating polyneuropathy (CIDP), Hypogammaglobulinemia and immunodeficiency diseases.

 

TOC

1.1 Company Overview

1.2 Company Snapshot

1.3 Operating Business Segment

1.4 Business Performance

1.5 Key Strategic moves and Development

 

LIST OF TABLES AND FIGURES

TABLE 1. CSL BEHRING SNAPSHOT

TABLE 2. CSL BEHRING OPERATING SEGMENTS

FIGURE 1. CSL BEHRING:REVENUE, 2013-2015, ($MILLION)

FIGURE 2. CSL BEHRING FINANCIAL REVENUE OF BY GEOGRAPHY (2013)

FIGURE 3. CSL BEHRING FINANCIAL REVENUE OF BY BUSINESS GROUP (2013)

FIGURE 4. CSL BEHRING FINANCIAL REVENUE OF BY BUSINESS GROUP (2013)

Purchase Options

 

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of the scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save the time of readers